Diabetes Therapy

Liraglutide improves glycemic control and body weight in diabetes

Published in Clinical Trials Week, September 5th, 2005

Researchers report the effects of liraglutide, a long-acting GLP-1 analogue, on glycemic control and body weight in subjects with type 2 diabetes in a recent issue of Diabetic Medicine.

According to a study from the United States, "Liraglutide (NN2211) is a long-acting GLP-1 analogue, with a pharmacokinetic profile suitable for once-daily administration. This multicenter, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on body weight and glycemic control in subjects with type 2 diabetes. Subjects (BMI 27-42 kg/m²) with type 2 diabetes who were previously treated with an OAD (oral...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2005-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry